Parabilis Medicines, Inc. (PBLS)
Company
Parabilis Medicines, Inc. (PBLS)
Jun 10, 2026
Biotechnology
Initial Public Offering / IPOIPO
Prospectus volume (424B4)670 m USD33,500,000 shares · 20 USD/share
We are a clinical-stage biopharmaceutical company built to develop transformative medicines addressing some of the most consequential, yet historically undruggable, protein targets driving human disease. We leverage our proprietary platform to pioneer a novel therapeutic modality, Helicons, which are stabilized helical peptides engineered to bind and precisely modulate proteins that have long been beyond the reach of conventional medicines.Â
Former names
| Name | Until |
|---|---|
| FOG PHARMACEUTICALS, INC. | Dec 2, 2022 |
Chart/Sentiment
Financials
Parabilis Medicines, Inc. (PBLS)
Source: SEC Company Facts · USD. Some values may be calculated; please verify them against the official SEC filings.







